Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues: |
| Cardiovascular | 1.7 | 1.7 | | | 2.1 | 1.6 | | |
| Device Protection | 2.2 | 2.4 | | | 2.2 | 2.1 | | |
| Women's Health | 2.4 | 2.3 | | | 1.8 | 1.6 | | |
| Orthobiologics | 3.9 | 6.7 | | | 6.5 | 6.2 | | |
| Total revenues | 10.3 | 13.1 | 12.7 | 12.4 | 12.6 | 11.5 | 10.9 | 11.5 |
| Revenue growth [+] | -18.5% | 13.5% | 16.6% | 7.9% | 3.9% | -10.8% | -12.9% | -2.5% |
| Cardiovascular | -17.4% | 11.6% | | | | | | |
| Device Protection | -1.0% | 14.5% | | | | | | |
| Women's Health | 31.6% | 40.5% | | | | | | |
| Orthobiologics | -39.1% | 6.6% | | | | | | |
| Non-Core Products | | | | 18.7% | | | | 102.7% |
| Cost of goods sold | 9.3 | 6.7 | 7.7 | 7.3 | 7.7 | 7.2 | 7.5 | 7.8 |
| Gross profit | 1.0 | 6.3 | 5.0 | 5.0 | 4.9 | 4.3 | 3.4 | 3.7 |
| Gross margin | 9.5% | 48.5% | 39.4% | 40.8% | 38.8% | 37.2% | 31.2% | 32.1% |
| Selling, general and administrative [+] | 7.6 | 9.0 | 8.5 | 9.4 | 10.1 | 8.8 | 7.7 | 8.3 |
| Sales and marketing | 3.6 | 5.4 | 5.1 | 4.9 | 5.4 | 4.8 | 4.5 | 4.8 |
| General and administrative | 4.0 | 3.7 | 3.4 | 4.5 | 4.7 | 4.0 | 3.2 | 3.5 |
| Research and development | 1.2 | 1.8 | 2.1 | 2.0 | 2.6 | 2.3 | 3.4 | 2.3 |
| EBITDA [+] | -6.9 | -3.6 | -4.6 | -5.4 | -6.9 | -5.9 | -6.8 | -6.0 |
| EBITDA growth | -0.6% | -39.7% | -31.9% | -9.7% | 88.4% | 113.5% | 124.5% | 247.1% |
| EBITDA margin | -66.6% | -27.3% | -36.4% | -43.5% | -54.6% | -51.4% | -62.4% | -52.0% |
| Depreciation | 0.1 | 0.1 | 0.9 | 0.9 | 0.1 | 0.1 | 0.9 | 0.9 |
| EBITA | -7.0 | -3.7 | -5.6 | -6.3 | -7.0 | -6.0 | -7.7 | -6.9 |
| EBITA margin | -67.6% | -28.0% | -43.8% | -51.0% | -55.3% | -52.1% | -71.0% | -60.1% |
| Amortization of intangibles | 0.9 | 0.8 | | | 0.9 | 0.8 | | |
| EBIT [+] | -7.8 | -4.5 | -5.6 | -6.3 | -7.8 | -6.8 | -7.7 | -6.9 |
| EBIT growth | -0.3% | -34.1% | -28.0% | -8.4% | 70.5% | 84.8% | 94.6% | 156.4% |
| EBIT margin | -75.9% | -34.5% | -43.8% | -51.0% | -62.0% | -59.5% | -71.0% | -60.1% |
| Non-recurring items [+] | 1.3 | 1.9 | 3.3 | 1.5 | 0.3 | 0.1 | 0.1 | 0.1 |
| Legal settlement | 1.3 | 1.9 | 3.3 | 1.5 | 0.3 | 0.1 | 0.1 | 0.1 |
| Interest expense | 1.5 | 1.5 | 1.6 | 1.3 | 1.2 | 1.2 | 1.3 | 1.3 |
| Interest expense | 1.5 | 1.5 | 1.6 | 1.3 | 1.2 | 1.2 | 1.3 | 1.3 |
| Other income (expense), net | | | 5.0 | -0.8 | | | | |
| Pre-tax income | -10.6 | -8.0 | -5.4 | -9.9 | -9.4 | -8.1 | -9.1 | -8.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | | | 0.0% | | | | | |
| Net income | -10.6 | -8.0 | -5.4 | -9.9 | -9.4 | -8.1 | -9.1 | -8.3 |
| Net margin | -103.2% | -61.3% | -42.6% | -80.0% | -74.4% | -70.9% | -83.5% | -72.4% |
| |
| Basic EPS [+] | ($0.65) | ($0.50) | ($0.39) | ($0.73) | ($0.69) | ($0.60) | ($0.87) | ($0.81) |
| Growth | -5.1% | -17.5% | -55.0% | -10.7% | 195.9% | 21.2% | -53.8% | -94.9% |
| Diluted EPS [+] | ($0.65) | ($0.50) | ($0.39) | ($0.73) | ($0.69) | ($0.60) | ($0.87) | ($0.81) |
| Growth | -5.1% | -17.5% | -55.0% | -10.7% | 195.9% | 21.2% | -53.8% | -94.9% |
| |
| Shares outstanding (basic) [+] | 16.2 | 16.1 | 13.8 | 13.7 | 13.6 | 13.6 | 10.4 | 10.2 |
| Growth | 19.1% | 19.0% | 32.4% | 33.5% | 33.2% | 32.7% | 266.2% | 1478.5% |
| Shares outstanding (diluted) [+] | 16.2 | 16.1 | 13.8 | 13.7 | 13.6 | 13.6 | 10.4 | 10.2 |
| Growth | 19.1% | 19.0% | 32.4% | 33.5% | 33.2% | 32.7% | 266.2% | 1478.5% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|